Citigroup Maintains Buy on Caris Life Sciences, Raises Price Target to $36
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Albert Hu maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $28 to $36.
Citigroup analyst Albert Hu maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $28 to $36.